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Studies by biointeraction chromatography of binding by phenytoin
metabolites to human serum albumin
Corey M. Ohnmacht, Shirley Chen, Zenghan Tong and David S. Hage*
Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304
*Corresponding author.Email: dhage@unlserve.unl.edu
Abstract: Biointeraction studies based on high performance affinity chromatography were used to investigate the binding of
human serum albumin (HSA) to two major phenytoin metabolites: 5-(3-hydroxyphenyl)-5-phenylhydantoin (m-HPPH) and
5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). This was initially examined by conducting self-competition zonal elution experiments in which m-HPPH or p-HPPH were placed in both the mobile phase and injected sample. It was found that
each metabolite had a single major binding site on HSA. Competitive zonal elution experiments using l-tryptophan, warfarin,
digitoxin, and cis-clomiphene as site-selective probes indicated that m-HPPH and p-HPPH were interacting with the indolebenzodiazepine site of HSA. The estimated association equilibrium constants for m-HPPH and p-HPPH at this site were 3.2
(±1.2) × 103 and 5.7 (±0.7) × 103 M−1, respectively, at pH 7.4 and 37 °C. Use of these metabolites as competing agents for injections of phenytoin demonstrated that m-HPPH and p-HPPH had direct competition with this drug at the indole-benzodiazepine site. However, the use of phenytoin as a competing agent indicated that this drug had additional negative allosteric interactions on the binding of these metabolites to HSA. These results agreed with previous studies on the binding of phenytoin
to HSA and its effects on the interactions of HSA with site-selective probes for the indole-benzodiazepine site.
Keywords: phenytoin metabolites, human serum albumin, high performance affinity chromatography, biointeraction studies

1. Introduction

this drug’s dose may cause larger-than-expected increases in
phenytoin’s serum concentration and apparent half-life, along
with lower levels for its metabolites [6].
When phenytoin is present in blood, it is highly bound to
the carrier protein human serum albumin (HSA) [3, 7]. A few
reports have indicated that phenytoin interacts at the warfarinazapropazone site of HSA [8, 9], while others have noted competition between phenytoin and digitoxin through the digitoxin site on HSA [10]. Recently Chen et al. have reported that
phenytoin interacts at several sites on this protein [7], with association equilibrium constants at the indole-benzodiazepine
and digitoxin sites of 1.04 (±0.05) × 104 and 6.5 (±0.6) × 103
M−1 at pH 7.4 and 37 °C; interactions involving allosteric effects and/or direct binding by phenytoin at the warfarin-azapropazone and tamoxifen sites of HSA were also noted.
Besides phenytoin, HSA is known to bind to a wide range
of other drugs and endogenous agents [9, 11, 12]. Although
several studies have examined the binding of phenytoin to
HSA, there is no known work that has examined the binding of

Phenytoin is one of the most widely-prescribed drugs for
the treatment of epilepsy [1, 2]. It has non-linear dose-dependent pharmacokinetics and is mostly excreted in bile as inactive metabolites, which are then reabsorbed from the intestinal tract and excreted in urine [3, 4]. The primary metabolites of phenytoin are 5-(3-hydroxyphenyl)-5-phenylhydantoin (m-HPPH) and 5-(4-hydroxyphenyl)-5-phenylhydantoin (pHPPH) (see Figure 1) [4].
Like other drug metabolites, m-HPPH and p-HPPH have
similar structures to their parent drug, which can cause these
to affect the distribution, action, and protein binding by phenytoin [4, 5]. Because phenytoin exhibits dose-dependent
pharmacokinetics, the apparent half-life of phenytoin changes with its dose and serum concentration. This occurs because
phenytoin is hydroxylated in the liver by an enzymatic system
that is saturable at high plasma levels of this drug, as occurs at
therapeutic concentrations [6]. As a result, small increases in
83
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Figure 1. Structures of phenytoin and its metabolites, m-HPPH and p-HPPH.

HSA to the phenytoin metabolites m-HPPH and p-HPPH. This
is of interest because 60–80% of phenytoin is metabolized into
these forms [13]. The goal of this work is to study the binding
of these metabolites to HSA by using high performance affinity chromatography and columns containing immobilized HSA.
Numerous reports using HPLC-based HSA columns have reported drug-binding properties that show good agreement with
those seen for soluble HSA [7, 14, 15]; this includes the recent
work performed with phenytoin in Reference [7].
In this current study, self-competition studies with mHPPH and p-HPPH will first be used to determine the number of binding regions and association equilibrium constants
for these metabolites with HSA. The location of these binding regions will be identified through studies using warfarin,
l-tryptophan, digitoxin, and cis-clomiphene as site-selective
probes [11, 16–19]. The competition of these phenytoin metabolites with phenytoin will also be considered. This should
result in a more complete picture of the binding of m-HPPH
and p-HPPH to HSA and of the relationship of this binding to
that of phenytoin and HSA.
2. Theory
2.1. General model and expressions
The binding of m-HPPH and p-HPPH to HSA was studied by
using the chromatographic method of zonal elution [16], [18],
[19], [20], [21] and [22]. In this technique, a competing agent
(I) is placed in the mobile phase at a known concentration and
continuously applied to an affinity column containing an immobilized ligand (L), such as HSA. Small amounts of an analyte (A) are then injected onto this system and the retention
time of the analyte is determined. If I and A compete for a single binding site on L, the following reactions and equilibrium
expressions can be used to describe the competition that takes

place between these agents in the column.
(1)
(2)
(3)
(4)
In these equations, KAL is the association equilibrium constant
for the binding of A to L, and KIL the association equilibrium
constant for the binding of I to L at the site of competition between A and I [16]. The symbol [ ] represents the molar concentration of a solute in the mobile phase, while { } represents
a surface concentration.
Equation (5) has been previously derived for the above
system to describe the retention of A as the value of [I] is varied [16].
(5)
In this equation, k is the retention factor for the injected solute
A, VM the column void volume, and mL the moles of binding
sites involved in the competition of A with L. If linear elution
conditions are present (i.e., the retention factor for A is independent of the amount of injected A), Equation (5) predicts
that a system with direct competition at a single site will give
a plot for 1/k versus [I] that is linear. From the ratio of the
slope to the intercept of this plot it is possible to obtain KIL,
the association equilibrium constant for I at its site of competition with A. It is also possible to obtain KAL from the intercept if independent values are available for mL and VM [16].
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tion with the site-selective probes l-tryptophan and digitoxin [11,
15]. This type of experiment is illustrated in Figure 2(b).
The simplest case for this type of experiment is one in
which a 1:1 interaction occurs between the injected analyte
(A) and competing agent (I) on the immobilized ligand. As
demonstrated previously [7, 19], this situation is described by
Equation (5) even if I (but not A) has multiple binding regions
on the ligand. In this case, the value of KIL that is obtained
from a plot of 1/k versus [I] gives the association equilibrium constant for I at its site of competition of A. If A is known
to bind to a given region on the ligand, this allows the competition of I at that site to also be examined and quantitated. By
using different probe compounds as the injected analyte, each
with a different binding region on the ligand, the interactions
of I at other sites on the same ligand can be examined in the
same manner [4, 11, 12, 16, 18, 19].
2.4. Detection of allosteric interactions

Figure 2. Typical chromatograms obtained in: (a) self-competition studies, as
illustrated with data for m-HPPH; and (b) competition studies with a site-selective probe, as represented by injections of l-tryptophan in the presence of
mobile phases containing various concentrations of p-HPPH. The experimental conditions are given in Section 3.

2.2. Self-competition studies
A special case arises for the system in Eqs. (1), (2), (3)
and (4) when A and I are the same compound. An example of
such an experiment is shown in Figure 2(a). In this situation
Equation (5) converts to the following form for a system with
single site binding, where [A] is the concentration of analyte
placed into the mobile phase [16].
(6)
This expression again results in a linear relationship for a plot
of 1/k versus [A]. However, the reciprocal of the slope now
gives the effective concentration of binding sites in the column (mL/VM), and the ratio of the slope to the intercept provides KAL. This makes such an experiment valuable in determining both the association equilibrium constant for an analyte with L and the amount of ligand sites present for this analyte in an affinity column [7, 11, 12, 16].
2.3. Direct competition with site-selective probes
Another advantage of zonal elution is it can be used to characterize site-specific equilibrium constants for an analyte that
has multiple binding sites on a ligand. For instance, this has been
used in recent work with phenytoin to show that this drug has at
least two binding sites on HSA, as demonstrated by its competi-

It is important to note that a linear response to Equation
(5) will be obtained only if there is direct competition between
A and I at a single type of binding site on L. If this is not the
case, then deviations from this linear response will be observed. One situation in which deviations can occur is if negative or positive allosteric effects are present. For instance, an
allosteric effect can occur if the ligand has two distinct sites
for A and I that affect one another.
If A or I is in the presence of L alone, then the association
equilibrium constants that will be observed for these solutes
will be KAL and KIL, respectively, as represented by the reactions in Equations (1) and (2). However, if both A and I are
present and their sites are allosterically linked, then the binding of A or I to L may cause a change in binding of the other agent at its respective site on the same ligand and result in a
change in their association equilibrium constants [16, 20]. For
a positive allosteric effect, this gives a non-linear response for
a plot of 1/k versus [I ], where k increases with [I ]. For a negative allosteric effect, the result is also a non-linear plot for 1/
k versus [I ], but with k now decreasing as [I ] increases. These
trends make it relatively easy to use affinity columns to qualitatively detect the presence of allosteric effects during soluteligand binding [7, 16]. In some situations, quantitative information on such effects can also be obtained [23].
3. Experimental
3.1. Reagents
The phenytoin (99% pure), m-HPPH (>98% pure), pHPPH (>98% pure), l-tryptophan (>98% pure), β-cyclodextrin (β-CD, >98% pure), digitoxin (97% pure) and HSA (99%
pure, essentially fatty acid free) were from Sigma (St. Louis,
MO, USA). HPLC-grade dimethylsulfoxide (>99% pure) was
from Alfa Aesar (Ward Hill, MA, USA). The cis-clomiphene
was supplied by the Marion Merrell Dow Research Institute
(Cincinnati, OH). The R-warfarin (>99% pure) was from Ultrafine (Manchester, England). Nucleosil Si-300 (7 μm parti-
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cle size, 300 Å pore size) was obtained from Macherey-Nagel (Duren, Germany). Reagents for the bicinchoninic acid
(BCA) protein assay were from Pierce (Rockford, IL, USA).
Other chemicals were reagent-grade or better. All aqueous solutions were prepared using water purified by a Nanopure system (Barnstead, Dubuque, IA, USA).
3.2. Apparatus
The chromatographic system consisted of a Jasco PU980 pump (Easton, MD, USA), a ThermoSeparations AS3000
autosampler (Riviera Beach, FL, USA), and a Milton Roy
SM3100 UV–vis absorbance detector (Riviera Beach, FL,
USA). The columns were maintained at 37 °C with a water
jacket from Alltech (Deerfield, IL, USA) and water circulator
from Brinkmann (Westbury, NY, USA). Chromatographic data
were collected using an in-house program written in Labview
5.1 (National Instruments, Austin, TX, USA). Retention times
were measured using PeakFit 4.12 (Jandel Scientific Software,
San Rafael, CA, USA). All columns were downward slurrypacked with an HPLC column slurry packer from Alltech.
3.3. Methods
3.3.1. Column preparation
The immobilized HSA support was prepared as described
previously [24]. In this technique, Nucleosil Si-300 was first
converted to diol-bonded silica [25]. This gave 306 (±3) μmol
diol groups (±1 S.D.) per gram of silica, as determined in triplicate by an iodometric capillary electrophoresis assay [26].
HSA was immobilized onto a portion of this support by the
Schiff base method in the following manner. The diol-bonded silica (about 1 g being required per column) was placed
in 10 mL of a 90:10 mixture of acetic acid and water along
with a mass of sodium periodate equal to the mass of diol silica (i.e., 1 g sodium periodate per 1 g diol-bonded silica). This
mixture was shaken for 2 h at room temperature using a wrist
action shaker, followed by centrifugation and washing of the
resulting aldehyde-activated support several times with deionized water. Next, 10 mL of pH 6.0, 0.1 M phosphate buffer was used to resuspend this support. This mixture was degassed under vacuum for 15 min and combined with 50 mg
HSA and 25 mg sodium cyanoborohydride per gram of silica.
The resulting mixture was kept in suspension by using a rotary stirrer and allowed to react at 4 °C for five days.
After immobilization, the resulting HSA support was
washed three times with pH 8.0, 0.1 M phosphate buffer. Any
remaining aldehyde groups on the support were reduced by
adding 17 mg sodium borohydride per gram of silica, which
was added slowly in three portions. This new mixture was
placed on a wrist action shaker for 2 h at room temperature.
The silica was then washed three times with pH 8.0, 0.1 M
phosphate buffer containing 0.5 M sodium chloride, followed
by several washes with pH 7.4, 0.067 M phosphate buffer. The
final support was stored in pH 7.4, 0.067 M phosphate buffer
at 4 °C until use. A control support was prepared in a similar
manner by taking diol-bonded silica through the entire immobilization procedure but with no HSA being added.
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The HSA and control supports were downward slurrypacked at 4000 psi (28 MPa) into separate 4.5 cm × 4.6 mm
i.d. stainless steel columns using pH 7.4, 0.067 M potassium
phosphate buffer as the packing solution. A portion of each remaining support was washed three times with deionized water, dried in a vacuum oven, and assayed in triplicate by the
BCA method for its protein content, using HSA as the standard and the control support as the blank [27]. This measurement gave an estimated protein content for the HSA support
of 28 (±2) mg HSA per gram of silica.
Both the HSA and control columns were used within four
months of preparation and over approximately 270 chromatographic runs. The stability of the HSA column was checked
periodically by monitoring the retention factors for m-HPPH
and p-HPPH in pH 7.4, 0.067 M phosphate buffer at 37 °C.
Only a 13–38% decrease in these retention factors was noted during the entire course of this study. Similar experiments
demonstrated that there was no significant change in the column void time (i.e., <2%) during these studies.
3.3.2. Chromatographic studies
All chromatographic experiments in this report were performed at 37 °C and 1 mL/min, unless otherwise noted. No
measurable changes in retention factors were seen when using
lower flow rates (i.e., down to 0.3 mL/min), indicating that the
given flow rate conditions were suitable for equilibrium constant measurements [7]. The typical backpressures for the HSA
and control column under these conditions were 520–670 psi
(4–5 MPa). All sample injections were made with a 5 μL sample loop unless otherwise indicated. The detection wavelengths
were as follows: p-HPPH and m-HPPH, 203 nm; phenytoin,
205 nm; l-tryptophan, 213 nm; R-warfarin, 308 nm, digitoxin, 205 nm; dimethylsulfoxide, 210 nm; and cis-clomiphene,
204 nm. Retention times were determined by using the first
statistical moment of each chromatographic peak.
The column void time was determined by injecting dimethylsulfoxide as a non-retained solute. Similar experiments
were used to correct for any non-specific binding by injecting the analytes on the control column. The retention factors
measured for each analyte on the control column were then
subtracted from those measured on the HSA column under
the same set of experimental conditions. This correction for
non-specific binding was 3–28% of the total retention measured on the HSA column for a given analyte. All retention
times were also corrected for the time required for solutes to
pass through the extra-column volume of the system, as determined by making injections of dimethylsulfoxide when no
column was present.
All samples and mobile phases were prepared using pH
7.4, 0.067 M phosphate buffer, with 2–4 replicates of all samples being injected under each set of conditions. The selfcompetition zonal elution studies with m-HPPH and p-HPPH
were performed by applying solutions containing 0 to 40 μM
m-HPPH or p-HPPH to the HSA and control columns while
injecting 50 μM solutions of these same analytes. Zonal elution studies investigating the competition of phenytoin with

BINDING BY PHENYTOIN METABOLITES TO HUMAN SERUM ALBUMIN

its metabolites were first performed by making injections of
50 μM phenytoin in the presence of 0–40 μM m-HPPH or pHPPH in the mobile phase. The roles of these analytes were
then reversed by placing 0–35 μM phenytoin in the mobile
phase while injecting 30–35 μM m-HPPH or p-HPPH. Zonal elution studies examining the competition between l-tryptophan or R-warfarin with m-HPPH and p-HPPH were performed in a similar manner, using injections of 10–100 μM ltryptophan or 20 μM R-warfarin as the sample.
The next set of experiments examined the use of digitoxin and cis-clomiphene as injected probes in the presence of mHPPH or p-HPPH in the mobile phase. This was accomplished
by using β-CD in the mobile phase to aid in the solubility of
digitoxin and cis-clomiphene [7, 11], as used in previous work
with these probes on other HSA columns [11, 18]. For these experiments, mobile phases containing 0–30 μM m-HPPH or pHPPH were prepared in solutions of 2 mM or 0.88 mM β-CD,
respectively; pH 7.4, 0.067 M phosphate buffer samples containing 5 μM digitoxin or cis-clomiphene in each of these respective
mobile phases were also prepared. These samples were applied
using an injection volume of 20 μL and a flow rate of 0.5 mL/
min or 2 mL/min for digitoxin and cis-clomiphene, respectively.
To ensure that linear elution conditions were present during this work, various concentrations (range, 5–100 μM) for
each analyte were injected onto both the HSA and control column in pH 7.4, 0.067 M phosphate buffer while their resulting
retention times were measured. No significant shifts in these
retention factors (i.e., random variations of less than 3%) were
noted over this range of concentrations. Solutions containing
l-tryptophan were used on the same day as their preparation.
All other samples were used within two months of preparation
and stored at 4 °C in pH 7.4, 0.067 M phosphate buffer. Each
solution was sonicated and degassed under vacuum for at least
15 min prior to use in chromatographic experiments.
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deviation of the true intercepts, giving differences of only 0.2
and 1.1% in these values for m-HPPH and p-HPPH.
The linearity of the plots in Figure 3 and the agreement
between the actual and best-fit intercepts of these plots supports a model in which both phenytoin metabolites are interacting at only one major site on HSA. From the slope/intercept ratios of these plots, it was possible to obtain the association equilibrium constants for m-HPPH and p-HPPH with
HSA. This gave estimated values of 4.0 (±0.1) × 103 M−1 and
5.2 (±0.3) × 103 M−1, respectively, at pH 7.4 and 37 °C. The
23% difference in these constants was statistically significant and indicated that the different positions of the hydroxyl
groups on m-HPPH and p-HPPH had a measurable effect on
the binding of these metabolites to HSA. It is also important

4. Results and discussion
4.1. Self-competition studies for m-HPPH and p-HPPH
The first set of experiments in this study used zonal elution
to examine the self-competition of m-HPPH and p-HPPH on
HSA. This was performed by injecting each of these phenytoin metabolites into the presence of a known concentration of
the same metabolite in the mobile phase. An example of such a
study is given in Figure 2(a), and the results are summarized in
Table 1. Although the retention factors measured in these studies were relatively low (range, 1.22–2.17), the precision of these
retention factors (±0.5–1.4%, one relative standard deviation)
was more than sufficient to allow the shifts in the m-HPPH and
p-HPPH peaks to be observed and determined in a reproducible fashion. The retention data obtained in these experiments
were analyzed according to a 1:1 direct competition model by
using Equation (6). The graphs this produced are given in Figure 3. It was found that plots of 1/k versus [A] were linear for
both metabolites, with correlation coefficients for m-HPPH and
p-HPPH of 0.9971 (n = 7) and 0.9942 (n = 7), respectively. The
best-fit intercepts for both metabolites were within one standard

Figure 3. Results of self-competition zonal elution studies for: (a) m-HPPH;
and (b) p-HPPH, as plotted according to Equation (6). The experimental conditions are given in the text. The best-fit lines were: (a) y = 0.00256 (±0.000
10) x + 0.7188 (±0.0019); and (b) y = 0.0033 (±0.0002) x + 0.6285 (±0.0029),
with correlation coefficients of 0.9971 (n = 7) and 0.9942 (n = 7), respectively. The error bars represent a range of ±1 S.D.
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to note that these values are significantly less (i.e., 20–68%
lower) than the association equilibrium constants that have
been measured on similar columns for phenytoin [7].
As noted in recent theoretical studies [28, 29], the observed
peaks in self-competition studies are actually due to analyte in
the mobile phase that has been displaced by the sample rather than due to the injected analyte, which elutes slightly later
as a normally unobservable mass peak. This means the retention factors in Table 1 are lower than those for the true peak of
interest (i.e., the mass peak), which would give high estimates
for association equilibrium constants determined according to
Equation (6). However, it is possible to determine the maximum size of this error based on the estimated separation factor
(α) between the mass peak and displacement peak, as described
in Reference [28]. Under the conditions used in this study this
gave a maximum difference of only 7–12% in the desired and
observed retention factors. This same issue was not a problem
in later studies using site-selective probes or phenytoin as competing agents (see Sections 4.2 and 4.3) since in these experiments the injected analyte was different from the competing
agent and had a mass peak that could be observed directly.
4.2. Competition of phenytoin metabolites with
site-selective probes for HSA
The next group of studies sought to determine the location of the major binding regions for m-HPPH and p-HPPH
on HSA. This was accomplished by examining the competition of these phenytoin metabolites with l-tryptophan and Rwarfarin, which are often used as probes for the indole-benzodiazepine and warfarin-azapropazone sites of HSA (i.e., Sudlow sites I and II) [15, 17, 18]. The data obtained in these experiments are summarized in Table 2. The first series of experiments used injections of l-tryptophan in the presence of
m-HPPH or p-HPPH as a mobile phase additive, as illustrated
earlier in Figure 2(b). A plot of 1/k versus [I] was then made
for each phenytoin metabolite. According to Equation (5), this
type of plot should yield a straight line if the probe and mobile phase additive are competing at a single type of site on
the immobilized ligand.
The plots obtained when using l-tryptophan as a site-selective probe are shown in Figure 4, where both phenytoin metabolites gave linear relationships when their data were analyzed according to Equation (5). The correlation coefficients of
the graphs for m-HPPH and p-HPPH were 0.9956 (n = 6) and
0.9986 (n = 7), respectively. In addition, both plots gave best-fit
intercepts that agreed within one standard deviation with the actual intercepts, with values that differed by only 0.3 and 0.4%.
This type of fit indicated that both metabolites had direct 1:1
competition with l-tryptophan. This led to the conclusion that
the indole-benzodiazepine site (i.e., Sudlow site II) was the major binding region on HSA for both m-HPPH and p-HPPH.
From the intercept and slope of the plots in Figure 4, it was
possible to obtain additional estimates of the association equilibrium constants for m-HPPH and p-HPPH with HSA. This
gave association equilibrium constants of 2.3 (±0.1) × 103 M−1

and 6.2 (±0.1) × 103 M−1, respectively, for these metabolites at
pH 7.4 and 37 °C. These values, which were now measured for
these metabolites specifically at the indole-benzodiazepine site,
are in reasonable agreement with those determined earlier from
the self-competition studies. These results again indicate that pHPPH has stronger binding to HSA than m-HPPH and that both
metabolites had weaker binding to HSA than phenytoin [7].
Similar studies were conducted using R-warfarin as a siteselective probe for the warfarin-azapropazone site of HSA
(i.e., Sudlow site I). However, in this case only small random
variations (±2%) in the retention factor of the injected probe
were noted as the mobile phase concentration of m-HPPH or
p-HPPH was varied. This indicated that these phenytoin metabolites were not binding at the warfarin-azapropazone site.
These results also indicated that these metabolites did not have
any appreciable allosteric effects on the binding of R-warfarin to HSA. This result differs from previous studies with Rwarfarin and phenytoin, where allosteric effects plus possible
direct competition were shown to exist between these agents
during their interactions with HSA [7].
Additional studies were conducted to investigate any interactions of the phenytoin metabolites at the digitoxin and
tamoxifen sites of HSA. This was accomplished by making
injections of digitoxin (a digitoxin site probe) or cis-clomi-

BINDING BY PHENYTOIN METABOLITES TO HUMAN SERUM ALBUMIN

Figure 4. Results of zonal elution studies using l-tryptophan as a site-specific probe injected in the presence of mobile phases containing known concentrations of: (a) m-HPPH; or (b) p-HPPH when analyzing the data according to
Equation (5). The best-fit lines were: (a) y = 0.00091 (±0.00004) x + 0.3933 (
±0.0006); and (b) y = 0.00129 (±0.00003) x + 0.2078 (±0.0006), with correlation coefficients of 0.9956 (n = 6) and 0.9986 (n = 7), respectively. The error
bars represent a range of ±1 S.D.
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The first series of zonal elution experiments in this section were performed by injecting trace amounts of phenytoin
into mobile phases that contained known concentrations of its
metabolites. Figure 5 shows the plots obtained when the data
were analyzed using a 1:1 direct competition model, as represented by Equation (6). These plots gave linear responses,

phene (a tamoxifen site probe) in the presence of mobile phases that contained known levels of m-HPPH or p-HPPH. For
both digitoxin and cis-clomiphene only small random variations (±1–4%) in their retention factors were observed as the
mobile phase concentration of m-HPPH or p-HPPH was varied. The digitoxin site has been found previously to bind phenytoin [7], but the results obtained in this current study indicate that m-HPPH and p-HPPH do not have significant interactions at this site. This may be related to the greater polarity of these metabolites versus phenytoin, which would tend to
decrease the importance of non-polar interactions in the binding of these compounds to HSA. Alternatively, this may result
from steric effects that prevent the binding of these metabolites to the digitoxin site due to the presence of the hydroxyl
groups on these compounds.
4.3. Competition of phenytoin with m-HPPH and p-HPPH
A third set of experiments investigated the competition
that occurs on HSA between m-HPPH and p-HPPH and their
parent compound, phenytoin. This was of interest because of
the differences noted earlier in this report concerning the association equilibrium constants and number of binding sites for
phenytoin compared to its metabolites. The results obtained in
these studies are summarized in Table 3.

Figure 5. Results of zonal elution competition studies using phenytoin injected into mobile phases containing known concentrations of: (a) m-HPPH; or
(b) p-HPPH. The best-fit lines were: (a) y = 0.00144 (±0.00007) x + 0.5325 (
±0.0014); and (b) y = 0.00169 (±0.00008) x + 0.4501 (±0.0017), with correlation coefficients of 0.9939 (n = 7) and 0.9939 (n = 7), respectively. The error
bars represent a range of ±1 S.D.
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as predicted for direct competition at a single site, with correlation coefficients of 0.9939 (n = 7) and 0.9939 (n = 7) for
the m-HPPH and p-HPPH data, respectively. The best-fit intercepts were within one standard deviation of the true intercepts, with differences in these values of only 0.14 and 0.55%
for m-HPPH and p-HPPH. It was possible from the slopes and
intercepts of these plots to again obtain estimates of the association equilibrium constants for m-HPPH and p-HPPH
with HSA. This gave values of 2.7 (±0.1) × 103 M−1 and 3.8
(±0.2) × 103 M−1, respectively, which agreed with the numbers calculated earlier from Figure 3 and Figure 4.
Figure 5 indicates that both m-HPPH and p-HPPH had direct competition with phenytoin on HSA. From the experiments described in the last section, it was further determined
that this competition must be occurring at the indole-benzodiazepine site. However, as also stated earlier, phenytoin is
known to have additional binding regions on HSA and to have
significant allosteric effects on solutes that bind to other sites
on this protein [7]. The experiments in Figure 5 did not allow such effects to be seen since phenytoin was present in
only a trace amount compared to its metabolites. To overcome
this limitation, the reverse experiment was next performed,
in which the phenytoin metabolites were injected into mobile
phases that contained known concentrations of phenytoin. The
results are shown in Figure 6.
When the data for the competition of p-HPPH with phenytoin were plotted according to the direct competition model in Equation (6), the results gave a good fit to a linear regression model, as shown in Figure 6(b), with a correlation coefficient of 0.9913 (n = 5). However, the association equilibrium constant estimated from this plot for phenytoin was 1.8 (±
0.1) × 103 M−1. This value is approximately an order of magnitude lower than that found in previous competition studies using a trace amount of phenytoin and l-tryptophan as a site-selective probe for the indole-benzodiazepine site [7]. As indicated in Reference [7], this decrease in binding strength for phenytoin can be explained by a negative allosteric effect between
phenytoin and itself as this drug binds to other regions on HSA.
This would also be expected to produce a mixed-mode interaction between phenytoin and p-HPPH, where phenytoin can undergo either direct competition with this metabolite or cause a
negative allosteric effect in the binding of p-HPPH to HSA.
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The presence of negative allosteric effects was more clearly indicated in the results for m-HPPH and phenytoin in Figure 6(a). In this case, when the data were plotted according to
the direct competition model in Equation (6) distinctly nonlinear behavior was noted. This behavior is consistent with a
model in which the binding of phenytoin to HSA is having direct competition plus a negative allosteric effect on the binding of its metabolite to HSA. A similar effect to that seen in
Figure 5 and Figure 6 has been also reported in earlier studies
examining the interactions on HSA between phenytoin with ltryptophan (i.e., the site-selective probe used in this current
study for the indole-benzodiazepine site) [7, 20].

Figure 6. Results of zonal elution competition studies using: (a) m-HPPH;
or (b) p-HPPH injected into the presence of mobile phases containing known
concentrations of phenytoin. The solid-lines show the best-fit response when
the data were analyzed according to a 1:1 direct competition model based on
Equation (5). The best-fit lines in these plots were: (a) y = 0.0022 (±0.0003) x
+ 0.9709 (±0.0051); and (b) y = 0.0019 (±0.0001) x + 1.0363 (±0.0024) with
correlation coefficients of 0.9709 (n = 5) and 0.9913 (n = 5), respectively. The
error bars represent a range of ±1 S.D.

BINDING BY PHENYTOIN METABOLITES TO HUMAN SERUM ALBUMIN

5. Conclusions
This report used HPLC-based immobilized HSA columns
to study binding by the phenytoin metabolites m-HPPH and pHPPH to HSA. The results are summarized in Table 4. Selfcompetition experiments indicated that these metabolites had
a single major binding site on HSA. Further work with siteselective probes indicated that the indole-benzodiazepine site
(i.e., Sudlow site II) was the location of this binding region.
Several estimates were obtained for the association equilibrium constants of these phenytoin metabolites with HSA.
These values ranged from 2.3 to 4 × 103 M−1 (best estimate,
3.2 (±1.2) × 103 M−1) for m-HPPH and 5.2–6.2 × 103 M−1
(best estimate, 5.7 (±0.7) × 103 M−1) for p-HPPH at pH 7.4
and 37 °C. For each of these estimates, p-HPPH had an association equilibrium constant that was 1.3–2.7 fold higher than
that for m-HPPH. This indicated the relative importance of the
hydroxyl group position of these compounds in determining
their overall binding strength to HSA.
Both m-HPPH and p-HPPH where found to have direct
competition with their parent compound, phenytoin, at the indole-benzodiazepine site of HSA. However, experiments using phenytoin as a competing agent indicated that this drug
also had negative allosteric interactions on the binding of
these metabolites to HSA. These results agree with previous
studies on the binding of phenytoin to HSA and its effects on
the interactions of HSA with site-selective probes for the indole-benzodiazepine site [7] and [20]. The results of this report also demonstrate the value of using HPLC-based HSA
columns in the study of drug/metabolite competition. In addition, these results indicate that significant differences can occur in both the binding strength and binding regions for drugs
and their metabolites on HSA.
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